T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis.

Candidemia and other forms of invasive candidiasis pose a significant diagnostic challenge. In order to provide the best treatment, it is important to accurately detect the fungal infection and identify the species. Historically, diagnosis of Candida infections depended upon three classical laboratory approaches: microbiologic, immunologic, histopathologic; and now includes new methods such as radiographic techniques, molecular, proteomic and biochemical methods. The T2Candida Panel has introduced a new class of infectious disease diagnostics that can rapidly detect and identify the causative pathogen of sepsis directly from a patient blood sample in a culture-independent manner. This test enables detection of Candida directly from the patient sample, a significant advance for the rapid and accurate diagnosis of invasive candidiasis.

[1]  R. L. Thompson,et al.  Microbiological and clinical evaluation of the isolator lysis-centrifugation blood culture tube , 1983, Journal of clinical microbiology.

[2]  Victoria J. Fraser,et al.  Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality , 2005, Antimicrobial Agents and Chemotherapy.

[3]  H. Prentice,et al.  Towards a targeted, risk‐based, antifungal strategy in neutropenic patients , 2000, British journal of haematology.

[4]  D. Horn,et al.  The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. , 2012, Diagnostic microbiology and infectious disease.

[5]  B. Alexander,et al.  Contemporary Tools for the Diagnosis and Management of Invasive Mycoses , 2006 .

[6]  C. Rodriguez-Gonzalez,et al.  Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. , 2014, The Journal of antimicrobial chemotherapy.

[7]  M. Kollef,et al.  Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study , 2010, BMC infectious diseases.

[8]  D. Kontoyiannis Echinocandin-based initial therapy in fungemic patients with cancer: a focus on recent guidelines of the infectious diseases society of america. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  A. Kwa,et al.  An Observational Study on Early Empiric versus Culture-Directed Antifungal Therapy in Critically Ill with Intra-Abdominal Sepsis , 2014, Critical care research and practice.

[10]  M. Pfaller,et al.  Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.

[11]  K. Garey,et al.  Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines , 2007, Pharmacoepidemiology and drug safety.

[12]  S. Magill,et al.  Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  K. Garey,et al.  FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  T. Kiehn,et al.  Large-scale clinical comparison of the lysis-centrifugation and radiometric systems for blood culture , 1985, Journal of clinical microbiology.

[16]  K. Garey,et al.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  K. Garey,et al.  T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Jan Grimm,et al.  Novel Nanosensors for Rapid Analysis of Telomerase Activity , 2004, Cancer Research.

[19]  T. Calandra,et al.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[20]  C. Clancy,et al.  Undiagnosed invasive candidiasis: incorporating non-culture diagnostics into rational prophylactic and preemptive antifungal strategies , 2014, Expert review of anti-infective therapy.

[21]  C. Charbonneau,et al.  Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[22]  A. Law,et al.  A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. , 2010, The Journal of antimicrobial chemotherapy.

[23]  Sean X. Zhang Enhancing molecular approaches for diagnosis of fungal infections. , 2013, Future microbiology.

[24]  K. Carroll,et al.  Comparison of BD Bactec Plus Aerobic/F Medium to VersaTREK Redox 1 Blood Culture Medium for Detection of Candida spp. in Seeded Blood Culture Specimens Containing Therapeutic Levels of Antifungal Agents , 2011, Journal of Clinical Microbiology.

[25]  M. Castanheira,et al.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  C. Gennings,et al.  Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  Jordi Rello,et al.  International study of the prevalence and outcomes of infection in intensive care units. , 2009, JAMA.

[28]  B. Erstad,et al.  Time to positive culture and identification for Candida blood stream infections. , 2009, Diagnostic microbiology and infectious disease.

[29]  C. Hull,et al.  Mitigation of human-pathogenic fungi that exhibit resistance to medical agents: can clinical antifungal stewardship help? , 2014, Future microbiology.

[30]  J. Timsit,et al.  Systemic antifungal therapy in critically ill patients without invasive fungal infection* , 2012, Critical care medicine.

[31]  H. Fredlund,et al.  Evaluation of a commercial multiplex PCR test (SeptiFast) in the etiological diagnosis of community-onset bloodstream infections , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[32]  L. Leibovici,et al.  PCR Diagnosis of Invasive Candidiasis: Systematic Review and Meta-Analysis , 2010, Journal of Clinical Microbiology.

[33]  Ralph Weissleder,et al.  Magnetic Nanosensors for the Detection of Oligonucleotide Sequences. , 2001, Angewandte Chemie.

[34]  M. Kollef,et al.  Treatment-related risk factors for hospital mortality in Candida bloodstream infections* , 2008, Critical care medicine.

[35]  M. Antonelli,et al.  Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study , 2012, Intensive Care Medicine.

[36]  K. Garey,et al.  Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of Candida species using seeded blood samples. , 2013, Diagnostic microbiology and infectious disease.

[37]  J. Weston,et al.  Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. , 2011, The Journal of antimicrobial chemotherapy.

[38]  H. Schønheyder,et al.  National Surveillance of Fungemia in Denmark (2004 to 2009) , 2010, Journal of Clinical Microbiology.

[39]  H. Schønheyder,et al.  National Surveillance of Fungemia in Denmark 2010-11 , 2012 .

[40]  C. Tseng,et al.  Multiplex PCR System for Rapid Detection of Pathogens in Patients with Presumed Sepsis – A Systemic Review and Meta-Analysis , 2013, PloS one.

[41]  Vasiliki Demas,et al.  Magnetic resonance for in vitro medical diagnostics: superparamagnetic nanoparticle-based magnetic relaxation switches , 2011 .

[42]  D. Denning,et al.  Excess mortality, length of stay and cost attributable to candidaemia. , 2009, The Journal of infection.

[43]  C. Clancy,et al.  Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  R. Lynfield,et al.  Multistate point-prevalence survey of health care-associated infections. , 2014, The New England journal of medicine.

[45]  M. Slavin,et al.  The case for antifungal stewardship , 2012, Current opinion in infectious diseases.

[46]  Mortimer Poncz,et al.  T2 magnetic resonance: a diagnostic platform for studying integrated hemostasis in whole blood--proof of concept. , 2014, Clinical chemistry.

[47]  D. Newton,et al.  Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  K. Garey,et al.  Clinical Practice Patterns in Hospitalized Patients at Risk for Invasive Candidiasis , 2014, The Annals of pharmacotherapy.

[49]  T. Calandra,et al.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[50]  David W. Denning,et al.  Hidden Killers: Human Fungal Infections , 2012, Science Translational Medicine.

[51]  M. Copland,et al.  The use of a risk group stratification in the management of invasive fungal infection: a prospective validation , 2004, British Journal of Haematology.

[52]  Hakho Lee,et al.  Ultrasensitive detection of bacteria using core-shell nanoparticles and an NMR-filter system. , 2009, Angewandte Chemie.

[53]  S. Seo,et al.  Effect of Antifungal Therapy Timing on Mortality in Cancer Patients with Candidemia , 2009, Antimicrobial Agents and Chemotherapy.

[54]  J. Perfect,et al.  Quantitation of Candida CFU in Initial Positive Blood Cultures , 2011, Journal of Clinical Microbiology.

[55]  K. Laupland,et al.  Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. , 2007, The Journal of antimicrobial chemotherapy.

[56]  K. Carroll,et al.  Blood cultures: key elements for best practices and future directions , 2010, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[57]  M. Prasad,et al.  Cost of Invasive Fungal Infections in the Era of New Diagnostics and Expanded Treatment Options , 2012, Pharmacotherapy.

[58]  M. Pfaller,et al.  Epidemiology of Invasive Mycoses in North America , 2010, Critical reviews in microbiology.

[59]  B. Wong,et al.  Comparative recovery of bacteria and yeasts from lysis-centrifugation and a conventional blood culture system , 1983, Journal of clinical microbiology.

[60]  C. Clancy,et al.  Performance of Candida real-time polymerase chain reaction, β-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[61]  W. Schaffner,et al.  Role of FKS Mutations in Candida glabrata: MIC Values, Echinocandin Resistance, and Multidrug Resistance , 2014, Antimicrobial Agents and Chemotherapy.

[62]  L. May,et al.  Better Tests, Better Care: Improved Diagnostics for Infectious Diseases , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  G. Warhurst,et al.  Bench-to-bedside review: The promise of rapid infection diagnosis during sepsis using polymerase chain reaction-based pathogen detection , 2009, Critical care.

[64]  S. Teutsch,et al.  Excess Mortality, Hospital Stay, and Cost Due to Candidemia: A Case-Control Study Using Data From Population-Based Candidemia Surveillance , 2005, Infection Control & Hospital Epidemiology.

[65]  M. Pfaller,et al.  The Epidemiology of Invasive Candidiasis , 2012 .

[66]  B. Healy,et al.  Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients , 2008, Journal of Clinical Pathology.

[67]  Ronald N. Jones,et al.  Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. , 2014, International journal of antimicrobial agents.

[68]  A. Caliendo,et al.  Molecular and Nonmolecular Diagnostic Methods for Invasive Fungal Infections , 2014, Clinical Microbiology Reviews.

[69]  Vasiliki Demas,et al.  T2 Magnetic Resonance Enables Nanoparticle-Mediated Rapid Detection of Candidemia in Whole Blood , 2013, Science Translational Medicine.

[70]  S. P. Bilir,et al.  The economic impact of rapid Candida species identification by T2Candida among high-risk patients. , 2015, Future microbiology.